Cerus Corporation (CU2.DE)

5,14 0,00 (0,00%) A partir del 05:35PM CEST. Mercado abierto.

Cerus Corporation

1220 Concord Avenue
Suite 600
Concord, CA 94520
United States
925 288 6000
https://www.cerus.com

Sector(es): 
Sector: 
Empleados a tiempo completo: 625

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. William M. Greenman	President, CEO & Director	963,37k	N/A	1967
Mr. Kevin D. Green	VP of Finance & CFO	565,14k	N/A	1972
Mr. Vivek K. Jayaraman	Chief Operating Officer	648,07k	N/A	1975
Ms. Chrystal Jensen	Chief Legal Officer & General Counsel	531,62k	N/A	1971
Dr. Richard J. Benjamin MBChB, Ph.D.	Chief Medical Officer	561,57k	N/A	1960
Dr. Laurence M. Corash	Co-Founder & Chief Scientific Officer	649,09k	178,41k	1944
Ms. Lori L. Roll	VP of Administration & Corporate Secretary	N/A	N/A	N/A
Mr. Matthew M. Notarianni	Senior Director of Investor Relations	N/A	N/A	N/A
Lainie Corten	Vice President of Global Marketing	N/A	N/A	N/A
Ms. Alicia Goodman	Chief Human Resources Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Gobierno corporativo

El ISS Governance QualityScore de Cerus Corporation, a día 1 de mayo de 2024, es 5. Las puntuaciones base son Auditoría: 7; Tablero: 3; Derechos de los accionistas: 7; Compensación: 6.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.